Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05502315 · ClinicalTrials.gov registry record · Phase 2
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
A Phase 2 study of Metastatic Cancer and Castration-resistant Prostate Cancer, sponsored by Rana McKay, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 4
- Study locations
NCT05502315: Recruiting Phase 2 study of Metastatic Cancer and Castration-resistant Prostate Cancer, sponsored by Rana McKay, MD.
NCT05502315 is a Phase 2 study of Metastatic Cancer and Castration-resistant Prostate Cancer that is actively recruiting participants, run by Rana McKay, MD. The registered enrollment target is 47 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05502315, a Phase 2 study of Metastatic Cancer and Castration-resistant Prostate Cancer, is actively recruiting participants, sponsored by Rana McKay, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Primary Outcome
The primary endpoint is the efficacy of treatment via assessment of 6 month rPFS defined by RECIST version 1.1 for soft tissue and Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases. rPFS is defined as the duration of time from the first day of the start of study treatment to time of radiographic progression or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cabozantinib
Study Locations (4)
California
- University of California San Diego - La Jolla
Illinois
- University of Chicago Medical Center - Chicago
Texas
- University of Texas Southwestern Medical Center - Dallas
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2027-04-12 |
| Phase | Phase 2 |
What NCT05502315 shows while recruiting
NCT05502315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05502315 reports a single indexed study location in California, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT05502315 about?
NCT05502315 is a clinical study titled "Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer". This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
What is the current status of trial NCT05502315?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2023-02-02. Estimated completion is 2027-04-12.
What conditions does trial NCT05502315 study?
This clinical trial studies the following conditions: Metastatic Cancer, Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT05502315?
The interventions under investigation include: Nivolumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT05502315?
This trial is sponsored by Rana McKay, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05502315 being conducted?
This trial has 4 study locations across California, Illinois, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05502315's enrollment target sits among peer trials
47 60th of 109 higher than 50 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI